Nonallergic rhinitis, sinonasal polyposis and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 108s Year: 2003
Treatment of inflammatory diseases of the nose Source: ISSN=1025-448x, ISBN=1-904097-19-21, page=165 Year: 2001
Treatment of nasal polyposis in aspirine sensitive asthma Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Rhinitis, nasosinusal polyposis and asthma: clinical aspects Source: ISSN=1025-448x, ISBN=1-904097-19-17, page=101 Year: 2001
Pathophysiology of airway hyperresponsiveness in patients with nasal polyposis Source: Annual Congress 2011 - Phenotyping airway diseases Year: 2011
Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002
Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Nasal polyposis and asthma: the chest physician's view Source: Eur Respir Monogr 2017; 76: 105-121 Year: 2017
Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020
Nasal polyposis and risk of the airway‘s inflammation development Source: Annual Congress 2008 - Risk factors for asthma versus asthma control Year: 2008
Nasal polyposis and asthma: the otorhinolaryngologist's view Source: Eur Respir Monogr 2017; 76: 87-104 Year: 2017
Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Effect of FESS on asthma patients with nasal polyposis and chronic sinusitis Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016
Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020